Although our current study did not evaluate treatment response, the presence of FSHR1 in VHL-associated hemangioblastoma and other VHL-associated tumors could similarly reflect a vascular phenotype amenable to target inhibition. The gene discussed is FSHR; the disease is hemangioblastoma.